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Primary malignant peritoneal 
mesothelioma associated with 
renal cell carcinoma  – A concise 
review based on a clinical case
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baseada num caso clínico
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RESUMO I O Mesotelioma peritoneal maligno é um tumor maligno relacionado frequentemente com exposição prolongada
a fibras de amianto, de mau prognóstico, de diagnóstico geralmente tardio, face à pouca expressão clínica na fase inicial da doença.
Como o mesotelioma evolui geralmente só na cavidade peritoneal, doentes seleccionados poderão ter maior sobrevivência se
for possível a peritonectomia extensa e quimioterapia hipertérmica intraperitoneal intraoperatória. Os autores referem a sin-
cronicidade ainda não descrita, de mesotelioma peritoneal maligno primário e carcinoma de Grawitz. São revistos concisamente:
a clínica destes tumores, síndromes paraneoplásicos (disfunção bioquímica hepática, emagrecimento extremo); etiopatogenia
da acção cancerígena das fibras de amianto; mecanismos de disseminação intraperitoneal; avaliação tomodensitométrica; im-
portância da imunohistoquímica no diagnóstico histopatológico; estadiamento; importância do tratamento multidisciplinar des-
tes tumores. GE - J Port Gastrenterol 2010;17:217-222.
PALAVRAS-CHAVE:Mesotelioma peritoneal maligno, Amianto, Hepatopatia paraneoplásica, Carcinoma de células renais, Ci-
rurgia cito-redutora, Quimioterapia hipertérmica intra-peritoneal intra-operatória.
ABSTRACT I Malignant peritoneal mesothelioma mesothelioma is associated with a long a exposure to asbestos and
usually has a poor prognosis. Short survival is due to late diagnosis, as patients are frequently pauci-symptomatic until advan-
ced stage. Since the tumor is usually confined to the peritoneal cavity, extensive peritonectomy and hypertermic intraoperative
intraperitoneal chemotherapy are associated with increased survival in selected patients. The synchronous occurrence of pri-
mary malignant peritoneal mesothelioma and renal cell carcinoma has not yet been described. A concise literature review of
symptomatology of peritoneal mesothelioma, paraneoplastic syndromes (dysfunctional biochemical hepatopathy, wasting syn-
drome); role of asbestos fibers in pathogenesis; mechanisms of intraperitoneal dissemination; CT scan evaluation; relevance
of immunohistochemistry for histopathologic diagnosis; staging of tumors; multidisciplinary approach for treatment of these
malignancies is performed. GE - J Port Gastrenterol 2010;17:217-222.
KEYWORDS:Malignant peritoneal mesothelioma, Asbestos, Paraneoplastic hepatopathy, Renal cell cancer, Cytoreductive sur-
gery, Hyperthermic intraoperative intraperitoneal chemotherapy.
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INTRODUCTION
Malignant Peritoneal Mesothelioma (MPM) is a rare ma-
lignancy, occurring at any age, although more commonly in
men in the 5th/6th decades of life due to increased occupa-
tional exposure to asbestos. MPM has a poor prognosis. In un-
treated cases, median survival ranges from 5 - 12 months.
Even in patients receiving traditional multimodality treat-
ment (surgery + chemotherapy), only exceptionally long-
term survival cases were mentioned1. The incidence of MPM
began to increase after 1930 with the frequently industrial use
of asbestos, and a peak in incidence is expected within the
next two decades due to the long latency period from as-
bestos exposure2. Exposure to asbestos dust/fibers occurs in
a variety of ways. Washing clothes of a family member who
worked with asbestos may be sufficient. Genetic predisposi-
tion appears to influence the greater occurrence of mesothe-
liomas in certain families.
MM arises from the mesothelial cells lining the pleura and
peritoneum (30%), and rarely in the pericardium or tunica
vaginalis3. Primarily exposure to the crocidolite variety has
been implicated in the pathogenesis of this malignancy. How-
ever, about half of the reported cases do not have a history of
asbestos exposure. Smaller particles of asbestos are more dan-
gerous than the larger fiber, remaining suspended in the air
where they can be inhaled, penetrating more easily and deeper
into the lungs. MPM usually has a shorter latency period but
can vary from 10 to 50 years, with symptoms presenting in 20
- 30 years after asbestos exposure as compared to 30 - 40
years for pleural mesothelioma4. Probably inhaled asbestos
fibers into the lung induce MPM through transport to the ab-
domen via the lymphatic system. Asbestos fibers also may be
deposited in the gut after ingestion of asbestos contaminated
sputum. Other possible risk factors are familial Mediterranean
fever and ports of prior radiation1, or after thorium, talc, eri-
onite or mica exposure, and also patients with diffuse lym-
phocytic lymphoma5.
Clinical history can be elusive, sometimes weight loss being
the only clinical symptom present for a long time, delaying the
diagnosis often until an advanced stage at the initial presen-
tation. Besides abdominal pain/abdominal distention, MPM
may manifest atypically with unusual paraneoplastic syn-
dromes (dysfunctional hepatopathy, wasting syndrome),
thrombocytosis, venous thrombosis, and hypoglycemia1.
MPM is usually confined to the surfaces of the ab-
domen/pelvis, rarely penetrating through the diaphragm and
involving pleural serosa, causing respiratory symptoms. In the
majority of patients, hematogenous or lymphatic metastases
to other sites usually do not occur, but metastases to the
parasternal, retroperitoneal, mediastinal, axillary, supraclav-
icular and cervical lymph nodes, lung, bone, liver, and um-
bilical areas (Sister Mary Joseph’s nodule), have been re-
ported5. Mortality is usually caused by intestinal obstruction,
fistula formation, and starvation6.
In addition to mesothelioma, exposure to asbestos increases
the risk of lung cancer in smokers, asbestosis (a noncancerous,
chronic lung ailment), and other cancers such as tumors of the
larynx, and kidney4.
CASE REPORT
A 78-year-old man was admitted on August 8, 2005 due to mas-
sive ascites. He was apparently well until five months prior to ad-
mission (PTA), when he started to develop anorexia, asthenia,
easy fatigability, progressive weight loss (15 kg), postprandial
fullness and abdominal swelling. Several days PTA, he noticed an-
kle edema, decreasing urine output, frequent borborygmi and in-
termittent lower abdominal colic. One day PTA, he had one
episode of vomiting. He denied any other symptom. During these
months the following exams were performed:  a chest R-ray re-
vealing bilateral randomly distributed pleural calcifications, nor-
mal barium swallow and barium enema, and a non-informative
abdominal ultrasonography. On questioning, he admitted to have
been exposed to asbestos 40 years ago when he handled a lot of
industrial bags that contained asbestos. On physical exam the pa-
tient was afebrile, BP 130/70 mmHg, HR 115 bpm, with no res-
piratory distress. His abdomen was very distended and tense
with ascites. A  vague mass on the right flank was identified. Liver
and spleen did not appear to be enlarged and there was no ab-
dominal collateral venous circulation or hernias. There were no
signs of liver failure. Prostate was slightly enlarged. Blood tests re-
vealed: Hb 10.0 g/dl, MCHC 33.2%; leukocytes 8.1x109/L (84.8%
N); platelets 5.27x109/L; normal PT and APTT; reticulocytes
37.0x109/L (20.0 - 100.0); ESR 86 mm; PCR 14.5 mg/dL (<1.00);
iron 14µg/dL (49 - 181); transferrin 129 mg/dL (190-375); ferritin
383 ng/mL (17.9 - 464.0); normal folic acid and vit. B12, albumin
2.36 g/dL; alkaline phosphatase 165 U/L (38-126); γ-GT 91 U/L
(15-73); other tests like glucose, BUN, creatinine, protein elec-
trophoresis and immunoglobulins, bilirrubin, alanine ami no-
 trans ferase and alanine aspartate transferase, LDH, amylase,
cholesterol, triglycerides, calcium, phosphorus, ionogram, mag-
nesium were normal. Serology for HBV, HCV and HIV were neg-
ative. Anti-nuclear, anti-smooth muscle and anti-mitochondrial
antibodies were negative. Several malignant markers: PSA; CEA;
CA 19.9; CA 15.3; α-FP were negative. Parentesis yielded 6000 ml
of yellow citrine non-turbid peritoneal fluid revealing parameters
of non-hypertensive portal ascites (SAAG < 0.737), with 0.2x109/L
leukocytes (neutrophils 39.9%, lymphocytes 29%), erythrocytes
0.01x1012/L, absence of malignant cells, protein 3.20 g/dL, glucose
62 mg/dL, LDH 1.118 U/L. The thoracic CT scan revealed bilateral
thickening and calcifications involving the anterior, posterior and
diaphragmatic pleura, with neither pleural fluid nor tumoral nod-
ules, and lungs were normal. The abdominal-pelvic CT scans
showed massive ascites with contrast-enhancement of several
peritoneal folds, together with heterogeneity and hypervascular-
ity of the great omentum and of the left perigastric ligaments (Fig.
1A). These findings were in favor of peritoneal carcinomatosis.
There was evidence of a solid tumor with a diameter of 4 cm at the
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level of the lower third of the right kidney, with low-contrast en-
hancement relative to the normal adjacent parenchyma (Fig. 1B),
and without evidence of either vascular invasion or of regional in-
volvement. Ascites re-accumulated quickly necessitating a re-
peated paracentesis, which again showed the same laboratory
characteristics. Nephrectomy of the right kidney (August 27 2008)
revealed two nodular lesions characterized by microscopy as re-
nal cell carcinoma, conventional type, nuclear anaplasia degree 1
(Fuhrman‘s classification) (Fig. 2), without invasion of the peri-re-
nal fat and of the hilar vessels and adrenal gland. The pyelocaliceal
tree and the ureter were normal and there was no thrombosis of
the renal vein. Postoperatively there was a transient worsening of
the renal function. A week after nephrectomy, there was re-accu-
mulation of ascites and paracentesis was again performed, with
the ascitic fluid showing the same laboratory characteristics. Af-
ter the third paracentesis, hepatomegaly was noted through in-
spection and by abdominal palpation. Due to the abnormalities of
the liver tests suggesting the possibility of intrahepatic cholesta-
sis, a liver biopsy was undertaken, which did not reveal any ab-
normality. The patient was discharged symptomatically improved,
but after ten days he was re-admitted due to re-accumulation of
ascites. The peritoneal fluid was then suspicious of malignancy.
We proceed to peritoneoscopy on September 16, 2008, which re-
vealed “tumor” implants on the abdominal wall, specifically in the
right hypochondrium and the right inguinal regions (it was not
possible to see the liver due to adherence of the colon and great
omentum). Although these findings were more in favor of peri-
toneal carcinomatosis, the microscopic examination showed
MPM, epithelial type, characterized by tubular structures and
gland-like spaces lined by cuboidal cells with vesicular nuclei and
eosinophilic cytoplasm (Fig. 3 A/B). Immunohistochemistry study
revealed the following data: CAM 5.2 +, EMA + (membranous pat-
tern), Ck 7 +, Ck 20 -, calretinin +, CEAp -, CD15 -) (Fig. 4 A/B).
With the diagnosis already confirmed, and with the patient’s age
and general state of health in mind, the patient was considered not
suitable to either traditional chemotherapy or cytoreductive sur-
gery, and even less for hyperthermic intraoperative intraperi-
toneal chemotherapy. Apart from intermittent paracentesis for
symptomatic relief of ascites, we tried to ameliorate anorexia and
asthenia by administering thalidomide in increasing doses. How-
ever, we were not able to surpass a dosage of 200 mg per day, as
the patient become progressively worse and died due to acute
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Fig. 1. Intravenous contrast-enhanced abdominal-pelvic axial CT-scans, revealing: A) mesentery nodularity.
B) Grawitz tumor of the right kidney and ascites.
Fig. 2. HEx400: Clear renal cell renal carcinoma.
bronchopneumonia. The patient’s family did not consent to a
necropsy.
DISCUSSION
Asbestos appears to act as a complete carcinogen with de-
velopment of mesothelioma in sequential stages of initia-
tion/promotion. Hypothetically, asbestos fibers act through di-
rect physical interactions with the mesothelium cells, in
conjunction with effects in interaction with inflammatory
macrophages cells, altering its function and secretory prop-
erties, ultimately creating conditions favoring the develop-
ment of mesothelioma, through the generation of increased
amounts of free radicals which promote asbestos carcino-
genicity. Asbestos also possess immunosuppressive properties.
The interactions between asbestos fibers and chromosomic
DNA, induce complex genetic abnormalities, most commonly
on chromosome 22. In experimental mesothelioma cell lines
deletion of tumor suppressor genes were identified4.
Milky spots in the greater omentum and pelvic peritoneum
have a role in tumor cell spread in the peritoneal cavity, being
the sites to which tumor cells migrate preferentially from the
peritoneal cavity, forming clusters within. Milky spots are
minute organelles containing accumulations of macrophages,
T and B lymphocytes around postcapillary venules, connected
by lymphatics, covered by leaky mesothelial cells, and may be
associated with mesothelioma metastases. Special peritoneal
lymphatic orifices (lymphatic stomata) connect with subperi-
toneal lymphatic channel and milky spots. Intraperitoneal
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Fig. 3. Peritoneal biopsy - Malignant peritoneal
mesothelioma: A) HEx100: tubular structures
and gland-like spaces. B) HEx400: the cells are
cuboidal with vesicular nuclei and eosinophil cy-
toplasm.
Fig. 4. Peritoneal biopsy – Malignant peritoneal
mesothelioma: Immunohistochemistry study: A)
400x:  CAM5.2 +.  B) 400x: calretinin + 
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free cancer cells specifically deposit in the lymphatic stomata
and proliferate in the submesothelial lymphatic space. Nu-
merous stomata are detected on the undersurface of the di-
aphragm, small bowel mesentery, greater omentum, appendix
epiploicae of the large bowel and the pelvic peritoneum. In
contrast, there are no lymphatic stomata on the liver capsule,
the surface of the spleen and the serosal surface of the small
bowel and stomach. Accordingly, the serosal surface of these
organs is involved only at the late phase of peritoneal dis-
semination7.
In MPM dissemination by cancer seeding and peritoneal
fluid production, result in disease progression. It seems that
fluid production is due to maintenance of a functional prop-
erty of normal mesothelial cells in malignant cells. As the
peritoneal fluid produced by mesothelial nodules increased,
dissemination to sites of peritoneal resorption occurs, result-
ing in widespread progression of malignant cells on peritoneal
surfaces and copious fluid production. In these patients the
peritoneal space becomes a free conduit for mesothelioma
cells to migrate from place to place. In producing of ascites
fluid, the cancer cells provide themselves with a carrier solu-
tion to disseminate throughout the abdominal/pelvic spaces,
explaining why patients with MPM often present with large
volume of ascites8.
Sugarbaker et al6 described three patterns of clinical pres-
entation of MPM: abdominal pain, abdominal distention, and
a combined presentation. These patterns appear to correlate
with the CT scan manifestations of MPM. The commonest
manifestation is the “dry-painful” type - CT revealing en-
hancing soft-tissue multiple small masses in the peritoneum,
omentum or peritoneal folds, or a single dominant mass in one
quadrant of the abdomen, with little or no ascites. Less com-
mon is the “wet type”, associated with abdominal distention
and ascites – the CT showing ascites associated with wide-
spread small nodules and plaques, without a dominant mass
(“debilitating ascites”). The third type is a combination of the
previous two, in which the patients may present with pain and
ascites. MPM has a tendency to spread along serosal surfaces
and for direct invasion of both solid and hollow intra-ab-
dominal organs, most commonly the colon and the liver. As
the disease evolves, the tumoral nodules become more con-
fluent plaque-like masses or looking omental “caking”. Occa-
sionally, the initial presentation may be fever of unknown
origin, night sweats, dysphagia, bowel obstruction, new onset
hernia, deep vein thrombosis and arterial occlusion. How-
ever, as MPM is rare, we have to consider a radiologic differ-
ential diagnosis with other malignant disease of the abdomen,
and also with diffuse benign diseases of the peritoneum3.
Routine laboratory tests are not useful in making the diag-
nosis. The most useful serum marker for diagnosis and follow-
up is the serum mesothelin-related protein (SMRP), which is
elevated in more than 84% of mesotheliomas with a sensitiv-
ity of 60% at diagnosis9. SMRP is also helpful for screening as-
bestos-exposed individuals for early evidence of mesothelioma. 
Confirmatory accurate diagnosis of MPM can be challeng-
ing, even though the radiologic CT scan imaging features can
suggest this entity. Cytologic diagnosis of aspirated fluid ob-
tained from paracentesis usually reveals an exudative process,
but with low yield of malignant cells (slightly more than 50%
of the cases), due to combination of marked difficulty in dif-
ferentiating malignant mesothelial cells from reactive
mesothelium and relatively small number of malignant cells
within the fluid. Diagnostic accuracy increases with core sam-
ple size, which can be done through peritoneoscopy, and with
immune-histochemistry study of the biopsy which is funda-
mental for the differential diagnosis 1,5. However, laparoscopy
can complicate the management by facilitating tumor dis-
semination to port sites, so limiting the puncture sites to
along the “linea alba” are recommended6.
Mesotheliomas have three base histological forms: (1) ep-
ithelial (the most frequent), (2) sarcomatoid and (3) mixed
(biphasic), according to the review by Weiss10. Positive stain
markers for MPM are cytokeratin, vimentin, EMA (membra-
nous pattern), Ck 5, calretinin, and thrombomodulin. The
best negative markers are CEA, Ber-EP4, CD15 (Leu-M1),
MOC-3. TTF1 and CA19.910. Electron microscopy may help in
the diagnosis, revealing ultra-structural features of MM, as tall
and thin microvilli on the cell surface, whose length exceeds
the width by a margin of 15:111.
Although there is no established staging system for MPM,
these tumors may be staged in four categories using the
TNM system: 1) a localized lesion able to be completely re-
sected; 2) disease contained within the abdominal cavity on
peritoneal and organ surfaces where debulking (the removal
of as much, but not all of the tumor) is possible, 3) disease
contained in the abdominal cavity with invasion of organs
(e.g. colon, liver); 4) disease extending outside the abdomi-
nal cavity. Sebbag et al12 proposed other staging system for
MPM – the TGM staging system, based on: 1) primary tumor
burden, before resection, evaluated by Peritoneal Cancer In-
dex (PCI), in which the sum of each peritoneal region lesion
size scores gives the PCI. Lesion sizes scores are classified
from 0: no tumor to 3. 
Prognosis of MPM varies with the tumor type, the epithelial
one having a slightly longer survival than biphasic and sarco-
matoid types. Nevertheless, the most reliable predictor of sur-
vival is the overall distribution of the disease. The prognosis
is better for patients with solitary tumors compared with
those with diffuse intra-abdominal disease6. Other significant
predictive factors of survival are age and completeness of cy-
toreduction after treatment.
Regarding treatment of MPM, a large majority of patients
with MPM are first diagnosed with a large volume of disease
diffusely spread throughout the abdomen/pelvis, mostly at
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sites of peritoneal fluid resorption and at gravity dependent
sites. The small bowel surfaces and mesenteries are common
sites of peritoneal implants. But as the tumor is usually con-
fined to the peritoneal cavity at the time of initial diagnosis,
remaining there for much or every of the subsequent clinical
course, multimodality therapeutic regimens combining early
aggressive local/regional cytoreductive surgery of as much tu-
mor as possible and intraperitoneal chemotherapy should be
pursued to obtain a better prognosis, and complemented by
early postoperative chemotherapy and immunotherapy2. Cis-
platin is the most frequently chemotherapeutic agent used,
usually in association with pemetrexed8. The score of residual
peritoneal seeding after cytoreductive peritonectomy is the
principal prognostic indicator, but usually the results are dis-
appointing5. In selected patients able to support it, hyper-
thermic intraoperative intraperitoneal chemotherapy
(HIPEC), followed by early postoperative intraperitoneal
chemotherapy, is a good strategy for a much longer sur-
vival - 50% of patients alive at 5 years, in cases of epithelial
type of MPM8,13. The mortality rate of HIPEC ranges be-
tween 0% and 11%, and most cases of death are due to bowel
perforation, bone marrow suppression, respiratory failure,
methicillin resistant Staphylococcus aureus infection, and
pulmonary embolism. Those patients not suitable for cura-
tive resection have a median survival of only 6 to 9 months.
Targeted therapies are monoclonal antibodies and drugs tar-
geting vascular endothelial growth factor, platelet-derived growth
factor and epidermal growth-factor, disturbing the growth of
MPM2. Thalidomide is one of such drugs administered at a daily
dose of 100 mg per day, increasing the daily dose weekly by 100 mg
to a maximum dose of 500 mg per day, as tolerated. Thalidomide
appears to be useful in controlling the distressing profuse sweat-
ing that often accompanies end stage cancer, but without obtain-
ing tumor shrinking14. In our patient thalidomide was not useful.
Stauffer’s syndrome, one of several frequently associated
precursor paraneoplastic syndromes of primary or recurrent
disease in renal cell cancer (RCC), characterized by hepato-
splenomegaly, fever and weight loss, biochemical abnormalities
of liver function tests (alkaline phosphatase and γ-glutamyl-
transferase), and pathologic changes consistent with non-spe-
cific hepatitis and absence of liver metastases, was considered
in our patient. Notwithstanding, ascites was not described in
Stauffer’s syndrome and in our patient biochemical abnormal-
ities persisted after nephrectomy15. Paraneoplastic cholestatic
hepatic dysfunction, frequently associated with fever, sweating,
wasting and severe weight loss, has been described in MPM2. In
our patient “apparent” hepatomegaly was noted through in-
spection and by palpation only after massive drainage of ascites.
Biochemical abnormalities were in favor of liver dysfunction
characterized by cholestasis. However, imaging by CT scan did
not revealed the presence of liver metastases, which was later
confirmed by a normal liver biopsy. To our knowledge, the syn-
chronous occurrence of MPM and RCC has not yet been de-
scribed. The prior exposure to asbestos in our patient is in favor
of a common oncogenic etiology in his case.
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